QL401 Tumor Targeted CD47 Blocker
Selective CD47 targeting to improve therapeutic windows
The ubiquitous expression of CD47 on normal cells, including red blood cells, presents a therapeutic challenge. Systemic targeting of CD47, by either anti-CD47 monoclonal antibodies or SIRPα-Fc fusion proteins, yields only moderate clinical benefit due to severe adverse side effects, mainly anemia. QLSF has developed tumor targeted CD47 bispecific antibodies with reduced binding to red blood cells while retaining potent phagocytic activation of macrophages in vitro and delayed tumor growth in vivo. Our lead candidate is well produced with drug-like properties.